title: Effects of hepatitis B surface antigen (HBsAg) positivity of donors in HBsAg(+) renal transplant recipients: comparison of outcomes with HBsAg(+) and HBsAg(-) donors.
abstract: OBJECTIVE
  The aim of this study was to determine the effects of hepatitis B surface antigen (HBsAg) positivity of the donors on graft survival and liver complications in HBsAg(+) renal transplant recipients.
  
  
  METHODS
  A group of 55 patients who underwent renal transplantation (RTx) in our hospital between 2001 and 2012 were included in the study. Patients were divided into 2 groups. Group 1 (n = 50) consisted of HBsAg(+) renal transplant recipients (RTR) whose donors were HBsAg(-). In Group 2 (n = 5), RTR and donors were both HBsAg(+). Lymphocyte cross matches, number of mismatches, donor types, renal replacement treatment modalities, drugs of induction treatment, and preoperative hepatitis B virus DNA titers of the groups were similar. In Group 1, 42 patients were taking lamivudine, 3 patients were taking entecavir, and 5 patients were taking tenofovir. All of the patients in Group 2 were taking lamivudine. Patient and graft survival rates, graft functions, acute hepatitis rates, acute rejection rates, and other clinical outcomes of the groups were compared.
  
  
  RESULTS
  Demographic data of the groups were similar. Acute rejection rates (P = 0.458), graft survival rates (P = 0.515), and patient survival rates (P = 0.803) were also similar. No significant difference was found between the groups in terms of acute hepatitis rate (P = 0.511), glomerular filtration rate (calculated by Modification of Diet in Renal Disease formula) in the last follow-up (P = 0.988), alanine aminotransferase levels (P = 0.069), or delayed graft function rate (P = 0.973). Rates of chronic allograft dysfunction and new onset diabetes mellitus after transplantation were similar.
  
  
  CONCLUSIONS
  Our study revealed that, RTx from HBsAg(+) donors to HBsAg(+) recipients is safe with antiviral treatment.
authors.affiliation: Department of Internal Medicine, Division of Nephrology, Akdeniz University Medical School, Antalya, Turkey.
authors.forename: V T
authors.initials: VT
authors.lastname: Yilmaz
authors.affiliation: Department of General Surgery, Akdeniz University Medical School, Antalya, Turkey.
authors.forename: I
authors.initials: I
authors.lastname: Aliosmanoglu
authors.affiliation: Department of General Surgery, Akdeniz University Medical School, Antalya, Turkey.
authors.forename: H
authors.initials: H
authors.lastname: Erbis
authors.affiliation: Department of General Surgery, Dicle University Medical School, Diyarbakir, Turkey.
authors.forename: B V
authors.initials: BV
authors.lastname: Ulger
authors.affiliation: Department of Internal Medicine, Division of Nephrology, Akdeniz University Medical School, Antalya, Turkey.
authors.forename: R
authors.initials: R
authors.lastname: Cetinkaya
authors.affiliation: Department of Internal Medicine, Division of Nephrology, Akdeniz University Medical School, Antalya, Turkey.
authors.forename: G
authors.initials: G
authors.lastname: Suleymanlar
authors.affiliation: Department of Internal Medicine, Division of Nephrology, Akdeniz University Medical School, Antalya, Turkey.
authors.forename: H
authors.initials: H
authors.lastname: Kocak
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage; D005260:Female; D005919:Glomerular Filtration Rate; D006084:Graft Rejection; D006085:Graft Survival; D006147:Guanine / Q000008:administration & dosage / Q000031:analogs & derivatives; D006509:Hepatitis B / Q000821:virology*; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D006515:Hepatitis B virus / Q000276:immunology*; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects*; D019259:Lamivudine / Q000008:administration & dosage; D008099:Liver / Q000821:virology; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control* / Q000821:virology; D000068698:Tenofovir / Q000008:administration & dosage; D014019:Tissue Donors; D066027:Transplant Recipients
chemical_list: D000998:Antiviral Agents; D006514:Hepatitis B Surface Antigens; D019259:Lamivudine; C413685:entecavir; D006147:Guanine; D000068698:Tenofovir
keywords: acute hepatitis; hepatitis B virus; lamivudine; liver failure; renal transplantation